Firefly Neuroscience (AIFF) Stock Price, News & Analysis

Company Overview

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function. In select studies, Firefly has incorporated lightweight sensor headbands to record electroencephalogram (EEG) signals, enhancing its ability to derive neurophysiological biomarkers. These digital measures are intended both for clinical trial sponsors evaluating investigational treatments and for healthcare providers seeking earlier intervention strategies.

Founded in 2017 and headquartered in the Greater Boston area, Firefly Neuroscience initially focused on Alzheimer’s disease and other forms of age‐related cognitive decline. The company collaborates with academic research centers, pharmaceutical partners and patient advocacy organizations to validate its tools across diverse populations. While its early clinical programs have been U.S.‐based, Firefly has signaled plans to expand its research partnerships and regulatory engagement in Europe and Asia.

Firefly Neuroscience is led by a management team with backgrounds in neuroscience, medical device development and digital health innovation. Through its integrated hardware-software approach, the company seeks to redefine how brain health is assessed, moving beyond episodic, clinic-based testing to continuous, data-driven insights that can accelerate drug development and enhance patient care.

Key Stats

• Today's Range: $2.03 to $2.08
• 50-Day Range: $2.03 to $3.05
• 52-Week Range: $1.86 to $17.20
• Volume: 235,352 shs
• Average Volume: 3.70 million shs
• Market Capitalization: $27.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Firefly Neuroscience Stock Analysis - MarketRank™

Firefly Neuroscience scored higher than 10% of companies evaluated by MarketBeat, and ranked 298th out of 317 stocks in the business services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Firefly Neuroscience.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Firefly Neuroscience is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Firefly Neuroscience is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.96% of the float of Firefly Neuroscience has been sold short.

Short Interest Ratio / Days to Cover

Firefly Neuroscience has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Firefly Neuroscience has recently decreased by 37.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Firefly Neuroscience does not currently pay a dividend.

Dividend Growth

Firefly Neuroscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.96% of the float of Firefly Neuroscience has been sold short.

Short Interest Ratio / Days to Cover

Firefly Neuroscience has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Firefly Neuroscience has recently decreased by 37.29%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: -0.44

News Sentiment

Firefly Neuroscience has a news sentiment score of -0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Business Services companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Firefly Neuroscience this week, compared to 1 article on an average week.

Search Interest

Only 5 people have searched for AIFF on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Firefly Neuroscience to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Firefly Neuroscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,015,775.00 in company stock.

Percentage Held by Insiders

Only 6.44% of the stock of Firefly Neuroscience is held by insiders.

Percentage Held by Institutions

Only 4.96% of the stock of Firefly Neuroscience is held by institutions.

AIFF Stock Analysis - Frequently Asked Questions

How have AIFF shares performed this year?

Firefly Neuroscience's stock was trading at $2.65 at the beginning of the year. Since then, AIFF shares have decreased by 22.6% and is now trading at $2.05.

How were Firefly Neuroscience's earnings last quarter?

Firefly Neuroscience, Inc. (NASDAQ:AIFF) posted its earnings results on Wednesday, August, 13th. The company reported ($0.14) earnings per share (EPS) for the quarter. Firefly Neuroscience had a negative net margin of 5,335.75% and a negative trailing twelve-month return on equity of 464.02%.

When did Firefly Neuroscience's stock split?

Shares of Firefly Neuroscience reverse split on Tuesday, August 13th 2024.The 1-3 reverse split was announced on Friday, August 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

How do I buy shares of Firefly Neuroscience?

Shares of AIFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Firefly Neuroscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Firefly Neuroscience investors own include Broadcom (AVGO), Paylocity (PCTY), Analog Devices (ADI), Advanced Micro Devices (AMD), ASML (ASML), Baidu (BIDU) and Bruker (BRKR).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 10/23/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Business Services
• Industry: Technology Services
• Sub-Industry: Computer Software
• Current Symbol: NASDAQ:AIFF
• Previous Symbol: NASDAQ:AIFF
• CIK: 803578
• Web: fireflyneuro.com
• Phone: (888) 237-6412
• Fax: 703-293-7979
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.46 million
• Net Margins: -5,335.75%
• Pretax Margin: -5,334.35%
• Return on Equity: -464.02%
• Return on Assets: -245.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.69
• Quick Ratio: 2.65

Sales & Book Value

• Annual Sales: $110 thousand
• Price / Sales: 248.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.05) per share
• Price / Book: -40.70

Miscellaneous

• Outstanding Shares: 13,450,000
• Free Float: 12,583,000
• Market Cap: $27.37 million
• Optionable: N/A
• Beta: 2.11